Tuesday, March 29, 2011

US Diabetic Retinopathy Market to Exceed $540 Million by 2015, According to New Report by Global Industry Analysts, Inc.

US Diabetic Retinopathy Marketplace to Exceed $ 540 Million by 2015, According to New Report by Global Market Analysts, Inc.












San Jose, California (Vocus) Could 31, 2010

Diabetic retinopathy is a form of eye disease that occurs in people suffering from diabetes, leading to severe vision loss, and in some cases, even total blindness. Diabetic retinopathy is a collective term given to diverse abnormalities related with retinal tiny blood vessels that are inflicted with diabetes. Vision loss due to diabetic retinopathy is caused by two conditions: Diabetic Macular Edema is a form of non-proliferative diabetic retinopathy where fluid enters the macula, causing it to swell and thus make the vision blurred. Proliferative Diabetic Retinopathy is the final stage of diabetic retinopathy, where difficulties with circulation of blood cause specific retinal areas to turn into ischemic (deprived of oxygen). Proliferative Diabetic Retinopathy is a major trigger of vision loss in patients with diabetic retinopathy.


Drug therapy for diabetic retinopathy, however, is no longer a dubious proposition, as stated by the new market investigation report on Diabetic Retinopathy. Drugs such as Arxxant (Eli Lilly), Atacand (Astra Zeneca), Lucentis (Genentech/Novartis), Avastin (Genetech/Roche) and Dexamethasone are all in their late stage development and some of these drugs are expected to enter the market in the next few years. These drugs, when approved, would open new doors for the treatment of diabetic retinopathy, a illness that is presently being managed only by preventive measures and surgical intervention.


Key players profiled in the report include Allergan, Inc., Eyetech, Inc., Genentech, Inc., Isis Pharmaceuticals, Inc., MacuSight, Inc., OPKO Wellness, Inc., pSivida Corp., Quark Pharmaceuticals, Inc., Sirnaomics, Inc., and Vitreoretinal Technologies, Inc. amongst other people.


The report titled “Diabetic Retinopathy: A US Marketplace Report” announced by Global Business Analysts Inc., gives a comprehensive review of diabetic retinopathy marketplace scenario, current market trends, study and development, pipeline drugs, clinical trials, recent corporate developments, and focus on main businesses. The study analyzes market forecasts in terms of value sales for the US market.


For a lot more details about this comprehensive market study report, please visit –

http://www.strategyr.com/Diabetic_Retinopathy_Marketplace_Report.asp


About Global Business Analysts, Inc.

Global Business Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the organization is globally recognized as 1 of the world’s largest marketplace study publishers. The firm employs over 800 people worldwide and publishes more than 1100 full-scale research reports every year. In addition, the business also offers thousands of smaller analysis goods which includes organization reports, marketplace trend reports, and industry reports encompassing all significant industries worldwide.


Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press(at)StrategyR(dot)com

Web Site http://www.StrategyR.com/


###









Attachments


















Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.











Much more Treatments For Diabetic Retinopathy Press Releases

0 comments:

Post a Comment